Australian firm presses on with COPD (chronic obstructive pulmonary disease) theranostic
This article was originally published in Clinica
Executive Summary
Australian company Pharmaxis has completed the enrolement phase of a clinical trial of its Aridol theranostic test in patients with chronic obstructive pulmonary disease (COPD). The test is already approved in Australia to identify asthma patients who will respond to inhaled steroid therapy, by detecting "steroid responsive inflammation".